Multiple sclerosis: Introduction, Risk Factors, Diagnosis and TreatmentEnriqueAlvarez93
Introduction about Multiple Sclerosis.
Risk factors affect to Multiple Sclerosis.
When to Suspect Multiple Sclerosis.
Evaluation and Diagnosis of Multiple Sclerosis.
How to treatment of Multiple Sclerosis.
Treatment of Multiple Sclerosis with Monoclonal Antibody.
Multiple sclerosis: Introduction, Risk Factors, Diagnosis and TreatmentEnriqueAlvarez93
Introduction about Multiple Sclerosis.
Risk factors affect to Multiple Sclerosis.
When to Suspect Multiple Sclerosis.
Evaluation and Diagnosis of Multiple Sclerosis.
How to treatment of Multiple Sclerosis.
Treatment of Multiple Sclerosis with Monoclonal Antibody.
Here is very good and amazing presentation on Multiple sclerosis ..its about brain
read this carefully and work on this because the work on brain is very good for future research...
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS , the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.
Motor neuron disease is a rare disease it doesn't have any cure here in this video I have tried playing what is mnd its types causes how to diagnose and its management plan
Here is very good and amazing presentation on Multiple sclerosis ..its about brain
read this carefully and work on this because the work on brain is very good for future research...
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS , the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.
Motor neuron disease is a rare disease it doesn't have any cure here in this video I have tried playing what is mnd its types causes how to diagnose and its management plan
A wonderful and interesting presentation on Multiple Sclerosis! It includes videos, pictures and great insight into the possible cure for MS. I truly hope whoever downloads it enjoys it as much as I do. Blessings!
Important de știut:
• Pentru toţi cei interesaţi, care studiază cu seriozitate Cuvântul lui Dumnezeu, avem disponibile şi alte materiale, atât în limba
română, cât şi în engleză. Contactaţi-ne la adresa fundaţiei pentru o listă a acestor materiale.
• În cazul în care unele publicaţii nu sunt disponibile în momentul comenzii, vă rugăm să reveniţi ulterior. Noi retipărim mereu
publicaţiile care au stocul epuizat.
• În limita posibilităților, vom încerca să acoperim și cheltuielile de transport, atât în țară cât și în străinătate.
• Pe site-ul nostru, www.abaptistvoice.com, veţi găsi multe alte resurse în format electronic, iar pe blogul http://
adunareaharulsuveran.wordpress.com veţi găsi informaţii despre viaţa adunării noastre. Vă aşteptăm cu drag.
• Avem disponibile publicații și materiale de evanghelizare gratuite și în limbile engleză, franceză, germană și rusă.
Un document d'aide pour réaliser un cahier des charges le plus complet possible tout en restant clair et simple.
Atelier/Rencontre Animation Numérique du Territoire Office de Tourisme Val de Cher Saint-Aignan - Février 2015.
Multiple sclerosis is generally referred to as an autoimmune disease or disorder in which the nerve cells of brain and spinal cord are attacked by patients own immune system.
The patient's bodys immune system perceives myelin sheet as an intruder and attack it resulting in damage due to which this sheet no longer carry the messages properly causing the message transmission process to be slowed, distorted or stopped altogether.
At present there is no cure available for multiple sclerosis, however, using certain drugs such as interferon’s, exercise and physiotherapy it is possible to manage the attacks and symptoms.
Researchers hope that stem cell therapies may provide new approaches that can both prevent damage and enable us to repair it.
Creando el mapa de la susceptibilidad genética y un modelo de patogénesis en ...Fundación Ramón Areces
Ciclo de conferencias y debates en Ciencias.
Fundación Ramón Areces-Nature Publishing Group.
Jorge R. Oksenberg. Universidad de California, San Francisco, EE. UU.
Madrid, 2 de febrero de 2012
Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body.
No one knows what causes MS. It may be an autoimmune disease, which happens when your body attacks itself. Multiple sclerosis affects women more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak or walk. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help.
Epstein-Barr virus genetic variants are associated with multiple sclerosis.Mutiple Sclerosis
Rosella Mechelli, Caterina Manzari, Claudia Policano, Anita Annese, Ernesto Picardi, Renato Umeton, Arianna Fornasiero, Anna Maria D’Erchia, Maria Chiara Buscarinu, Cristina Agliardi, Viviana Annibali, Barbara Serafini, Barbara Rosicarelli, Silvia Romano, Daniela F. Angelini, Vito A.G. Ricigliano, Fabio Buttari, Luca Battistini, Diego Centonze, Franca R. Guerini, Sandra D’Alfonso, Graziano Pesole, Marco Salvetti, Giovanni Ristori
OBJECTIVE:
We analyzed the Epstein-Barr nuclear antigen 2 (EBNA2) gene, which contains the most variable region of the viral genome, in persons with multiple sclerosis (MS) and control subjects to verify whether virus genetic variants are involved in disease development.
METHODS:
A seminested PCR approach and Sanger sequencing were used to analyze EBNA2 in 53 patients and 38 matched healthy donors (HDs). High-throughput sequencing by Illumina MiSeq was also applied in a subgroup of donors (17 patients and 17 HDs). Patients underwent gadolinium-enhanced MRI and human leucocyte antigen typing.
RESULTS:
MS risk significantly correlated with an excess of 1.2 allele (odds ratio [OR] = 5.13; 95% confidence interval [CI] 1.84-14.32; p = 0.016) and underrepresentation of 1.3B allele (OR = 0.23; 95% CI 0.08-0.51; p = 0.0006). We identified new genetic variants, mostly 1.2 allele- and MS-associated (especially amino acid variation at position 245; OR = 9.4; 95% CI 1.19-78.72; p = 0.0123). In all cases, the consensus sequence from deep sequencing confirmed Sanger sequencing (including the cosegregation of newly identified variants with known EBNA2 alleles) and showed that the extent of genotype intraindividual variability was higher than expected: rare EBNA2 variants were detected in all HDs and patients with MS (range 1-17 and 3-19, respectively). EBNA2 variants did not seem to correlate with human leucocyte antigen typing or clinical/MRI features.
CONCLUSIONS:
Our study unveils a strong association between Epstein-Barr virus genomic variants and MS, reinforcing the idea that Epstein-Barr virus contributes to disease development.
Effects of Antioxidants on Age and Multiple Sclerosis-Related Oxidative Stressarsosa
Abstract: Multiple sclerosis (MS) is a chronic and debilitating disease of the central nervous system (CNS). The pathogenesis of MS involves neurodegeneration which may be due to oxidative stress. Antioxidants such as vitamins have been studied as modifiers and biomarkers of oxidative stress in MS patients. MS progression, specifically that in which relapsing-remitting multiple sclerosis (RRMS) transitions to secondary-progressive multiple sclerosis (SPMS), is independent of disease onset and duration, but correlated with age. Because of the neurodegenerative effects of oxidative stress and the age-dependent course of MS, it is possible that the transition from RRMS to SPMS is caused by levels of oxidative stress that may increase with age. This study investigates the role of antioxidants α-tocopherol, glutathione, and uric acid on oxidative stress and subsequent MS progression. Further, I intend to compare the different effects of antioxidant supplements on RRMS patients, SPMS patients, and relatively healthy individuals based on cerebrospinal fluid and serum samples.
Preliminary report describing a targeted sequencing study in 1500 MS cases and 1500 controls. I presented this at the ASHG 2011 session on large scale resequencing.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
2. introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central
nervous system (CNS) characterized by the breakdown of the insulating
myelin sheath that covers the nerve axons in the CNS and subsequent
degeneration of axons.
MS affects approximately 400,000 people in the USA and more than 2.1
million people worldwide, but the incidence has increased in the last five
decades, particularly in women (3.6/100,000 person /years) compared to
men (2.0/100,000 person /years)
4. Genetics
The major histocompatibility complex (MHC) region on chromosome
6p21.32 is the first identified MS risk locus.
HLA-DRB1*1501 allele conferring a ~3-fold risk increase. As well as
DRB1*1303 conferred further risk.
IL7RA(encoding the interleukin receptor 7A) was initially assessed and
reported as a putative MS risk gene.
IL2Rα were found to be significantly associated with relatively risk of
MS.
CYP27B1, a gene associated with vitamin D metabolism.
5. Genetics
On the other hand, HLA-DRB1*14 carries such a protective effect that it
completely abrogates the increased risk of HLA-DRB1*15.
GWAS implicate genes coding for cytokine pathways (CXCR5, IL-2RA, IL-
7R, IL-7, IL-12RB1, IL-22RA2, IL-12A, IL-12B, IRF8, TNFRSF1A,
TNFRSF14, TNFSF14) .
Costimulatory (CD37, CD40, CD58, CD80, CD86, CLECL1) and signal
transduction (CBLB, GPR65, MALT1, RGS1, STAT3, TAGAP, TYK2).
8. Infection
little direct evidence supports the concept of a role for viral infection.
Innumerable efforts to culture a virus from autopsy-derived or biopsy
material have yielded no consistent result.
human T-cell lymphotropic virus type 1 [HTLV1]) have proven negative.
Human herpesvirus 6 (HHV6), Epstein-Barr virus (EBV), and Chlamydia
pneumoniae have been the focus of interest.
High serum levels of EBV antibodies have also been associated with an
increased risk of MS.
10. Vitamin D
MS patients typically have lower serum 25(OH)D levels than healthy controls .
Polymorphisms in the vitamin D receptor (VDR) gene have been of particular
interest.
candidate gene approach include two vitamin D metabolism-related genes,
CYP2R1 [which encodes the enzyme responsible for the conversion of vitamin
D to 25(OH)D] and DBP/GC (encoding the vitamin D-binding protein)
these inverse associations could also be explained by a direct effect of UVB
radiation, which has immunosuppressive effects independent from vitamin D.
11. Venous insufficiency
Zamboni and colleagues proposed that multiple sclerosis is caused by
abnormalities in the direction and pathway of cerebral venous flow, leading to
deposition of iron in the brain, which triggers an autoimmune reaction.
They reported that patients with multiple sclerosis had a higher frequency of
abnormalities of anatomy and flow in the internal jugular, deep cerebral,
vertebral and azygous veins than individuals without multiple sclerosis had.
13. Loss of old friends
Leibowitz and co-workers proposed that the prevalence of MS was linked
to a high sanitation level during childhood.
Epidemiological data demonstrating an inverse relationship between the
prevalence of autoimmune diseases and parasite infections, and more
specifically between MS and the helminth Trichuris trichuria.
There is decrease production of IL-12, TNF-α and IL-1β and increased
production of TGF-β and IL-10 in peripheral blood mononuclear cells
(PBMC's) and increased proliferation of CD4+CD25high regulatory T-cells
(Tregs) in infected person.
15. Clinical picture
patients may be grouped into four major categories based on the course of
disease:
1.Relapsing–remitting MS: the most common form, affecting about 85% of
MS patients.
2.Secondary progressive MS: may develop in some patients with
relapsing–remitting disease
3.Primary progressive MS: affects approximately 10% of MS patients.
Symptoms continue to worsen gradually from the beginning.
4.Progressive-relapsing MS: a rare form, affecting fewer than 5% of
patients. It is progressive from the start, with intermittent flare-ups of
worsening symptoms along the way.
20. What Is the Composition of the MS Plaque
Multiple sclerosis plaques may be characterized as active or inactive .
Macrophages are especially plentiful in active lesions which are
hypercellular and contain patchy infiltrates of autoreactive T cells and
antigen-nonspecific monocytes and macrophages within a zone of myelin
loss .
Macrophages and lymphocytes form prominent perivascular cuffs and
invade the parenchyma, whereas plasma cells and B cells tend to
concentrate in the perivascular region only
21. What Is the Composition of the MS Plaque
Chronic plaques display well-demarcated areas of hypocellularity with
myelin pallor or loss .
There are varying degrees of axonal loss, usually most obvious in the
lesional center .
There is typically a persistent but minor inflammatory response.
There are few or no oligodendrocytes.
22. Clinical picture
Cognitive Impairment.
34% to 65% of patients with MS have cognitive impairment.
The domains of verbal memory and attention/speed of information
processing were the most affected.
Comorbid depression, anxiety disorders, and emotional lability may
further affect cognitive performance.
Lesions located in frontal and parietal lobes showed stronger correlations
with tasks of processing speed, attention, and verbal memory.
23. Clinical picture
Affective Disorders.
Depression is the most common manifestation and is in part secondary to
the burden of having to cope with a chronic disease.
Suicide rates are higher in patients with MS than in the general population.
emotional “dyscontrol” is quite common, and patients oscillate frequently
between sad and happy states, at times without precipitant.
24. Clinical picture
Impairment of Visual Pathways
Optic neuritis (ON) is the most frequent type of involvement of the visual
pathways, usually presenting as an acute or subacute unilateral syndrome.
Bilateral simultaneous ON is rare in MS.
The Uhthoff phenomenon refers to a recurrence of a neurological
symptom (e.g., visual blurring) following an increase in body temperature.
25. Clinical picture
Impairment of Ocular Motor Pathways
the involved nerves are, in decreasing order of frequency, cranial nerves
VI, III, and (rarely) IV.
acquired pendular nystagmus, in which there are rapid small-amplitude
pendular oscillations of the eyes in the primary position, resembling
quivering jelly.
Internuclear ophthalmoplegia (INO), Convergence is preserved. When
present bilaterally, it is usually coupled with vertical nystagmus on upward
gaze.
One and half syndrome.
26. Clinical picture
Impairment of Other Cranial Nerves.
Facial myokymia, a fine, undulating wavelike facial twitching, and
hemifacial spasm.
Unilateral facial paresis can occur, but taste sensation is almost never
affected.
Vertigo is a reported symptom in 30% to 50% of patients with MS and is
commonly associated with dysfunction of adjacent brainstem or cranial
nerves.
Malfunction of the lower cranial nerves is usually of the upper motor
neuron type (pseudobulbar syndrome)
27. Clinical picture
Impairment of Sensory Pathways
The sensory features can reflect spinothalamic, posterior column, or
dorsal root entry zone lesions. The sensory symptoms are commonly
described as numbness, tingling, pins and needles.
The most frequent sensory abnormalities on clinical examination are
varying degrees of impairment of vibration and joint position sense.
Brown-Séquard syndrome.
the “numbclumsy hand” syndrome is a characteristic but uncommon
28. Clinical picture
Impairment of Motor Pathways.
Paraparesis or paraplegia occurs more frequently than significant
weakness in the upper extremities.
Amyotrophy, when observed, most frequently affects the small muscles of
the hand; lesions of the motor root exit zones may produce muscle
denervation secondary to axon loss.
29. Clinical picture
Impairment of Cerebellar Pathways
gait imbalance, difficulty performing coordinated actions with the arms,
and slurred speech.
dysmetria, decomposition of complex movements, and hypotonia, most
often observed in the upper extremities.
An intention tremor
Ocular findings of nystagmus, ocular dysmetria, and frequent refixation
saccades.
Speech can be scanning or explosive in character.
In severe cases, complete astasia (inability to stand),
30. Clinical picture
Impairment of Bladder, Bowel, and Sexual Functions
urinary urgency, usually the result of uninhibited detrusor contraction,
reflecting a suprasegmental lesion.
As the disease progresses, urinary incontinence due to urgency becomes
more frequent.
With involvement of sacral segments of the spinal cord, symptoms of
bladder hypoactivity may evolve (e.g., decreased urinary flow, interrupted
micturition, incomplete bladder emptying).
31. Clinical picture
Impairment of Bladder, Bowel, and Sexual Functions
An atonic dilated bladder that empties by overflow results from loss of
perception of bladder.
A dyssynergic voluntary sphincter that interrupts bladder emptying will lead to
frequent, small-volume urinations combined with a large postvoid residual.
Constipation is more common than fecal incontinence.
Sexual dysfunction, although frequently overlooked, occurs commonly in MS.
Approximately 50% of patients become completely sexually inactive because of
their disease, and an additional 20% become less sexually active.
32. Tumefactive MS
Tumefactive MS is an acute tumor-like MS variant in which some patients
with demyelinating disease present with large (>2 cm) acute lesions, often
associated with edema or ring enhancement .
There may be mass effect, with compression of the lateral ventricle and
shift across the midline. Although there is no consensus regarding
nomenclature.
33. Tumefactive MS
The clinical abnormalities in such patients are variable; they may be very
slight even in a patient with a massive lesion, while confusion,
hemiparesis, or neglect syndrome can be seen in another patient with a
lesion that appears no different.
Typically, much of the T2-bright lesion volume on brain MRI is due to
edema and may be rapidly responsive to glucocorticoid treatment.
However, radiologic improvement with glucocorticoids can also occur with
glioma or with central nervous system lymphoma and is therefore not a
useful diagnostic criterion.
Biopsy is often required.
36. Clinical picture
Prognosis.
Sex: benign course in women than in men.
Age at onset: Average is 29 to 32 years. Onset at an early age is a
favorable factor, whereas onset at a later age carries a less favourable.
Initial disease course: Relapsing form of the disease is associated with a
better prognosis than progressive disease
Initial complaints: impairment of sensory pathways or ON has been
found in several studies to be a favorable prognostic feature, whereas
pyramidal and particularly brainstem and cerebellar symptoms carry a
poor prognosis.
38. 3 of 4
1 Gd+ or 9 T2-hyperintense lesions if there is no enhancing lesion
At least one infratentorial lesion
At least one juxtacortical lesion
At least 3 periventricular lesions
MRI criteria dissemination in space
Barkhof et al criteria
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52. MAGNETIC RESONANCE SPECTROSCOPY
In active, newly formed MS plaques, NAA is slightly decreased and Cre,
Cho, and mI are increased. Lactate (Lac) peak is also increased,
suggesting energy failure. Over time, the initial surge in lipids, Cho, Lac,
and Cre may return to near normal.
In contrast to active plaques, chronic MS lesions show considerable
reduction in NAA, normal glutamate peaks, and elevation in mI.
Interestingly
53.
54.
55. Magnetization Transfer Imaging
Demyelination is visualized as a reduced proton exchange, or a decrease
in the magnetization transfer ratio (MTR), whereas an elevated proton
exchange, or increased MTR, is evidence of possible remyelination or
resolution of edema.
56.
57. Diffusion tensor imaging
Diffusion tensor imaging allows measurement of fractional anisotropy,
which reflects the degree to which the diffusion of water molecules follows
one direction versus many directions.
This technique is useful for assessing the integrity of white matter tracts,
which normally have a high degree of anisotropy due to their linear
arrangement and the preferred diffusion of water along the long axis of the
myelinated fibers .
Injury to nerve axons or myelin sheaths permits increased diffusion of
water across the white matter tract and thereby decreases fractional
anisotropy
58. Diffusion tensor imaging
Axial flair image (A) show two plaques in the internal capsule, one in the anterior
limb and one in the posterior limb. Diffusion tensor fractional anisotropy map (B)
shows asymmetric hypointensity (decreased anisotropy) in these regions
59. Cerebrospinal fluid analysis
The CSF appearance and pressure are grossly normal in MS.
The total leukocyte count is normal in two-thirds of patients, exceeds 15
cells/microL in <5 percent, and only rarely exceeds 50 cells/microL (a
finding that should raise suspicion of another etiology).
Lymphocytes are the predominant cell type, the vast majority of which are
T cells.
CSF protein (or albumin) level is usually normal.
60. Cerebrospinal fluid analysis
An abnormality of CSF IgG production as measured by the IgG index or IgG
synthesis rate is found in 90 percent of clinically definite MS patients .
Oligoclonal bands — OCBs are found in up to 95 percent of patients with
clinically definite MS .
OCBs represent limited classes of antibodies that are depicted as discrete bands
on agarose gel.
The presence of OCBs is not equivalent to a diagnosis of MS.
Antimyelin antibodies — Initial studies suggested that antibodies to myelin
oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) were
potential markers of MS .However, subsequent evidence suggests that these
antibodies are not associated with an increased risk of progression to MS or
with MS disease activi
61. Isoelectric focusing in an agarose gel at stable
pH (range 5.0–9.5) demonstrating the presence
of oligoclonal bands (arrows) in the CSF
(above) and not the serum (below).
The oligoclonal bands are different clones of
IgG that have migrated electrophoretically in
the stationary pH gradient until a steady state is
reached.
To be positive, two or more oligoclonal bands
must be detected in the CSF that are not present
in the serum of the patient.
62.
63. Evoked potentials
Evoked potentials are the electrical events generated in the central
nervous system by peripheral stimulation of a sensory organ.
The three most frequently used evoked potentials are somatosensory
evoked potentials (SSEP), visual evoked responses (VER), and brainstem
auditory evoked potentials (BAEP). Patients with clinically definite MS
have abnormal VERs in 50 to 90 percent of cases .
64.
65.
66. Treatment
IVMP 20 to 30 mg/kg/day for 5 days. A subsequent oral tapering
should be restricted to patients with:-
i) insufficient resolution of symptoms after steroid.
ii) recurrence of symptoms after steroid discontinuation.
Steroid tapering continued usually not exceeding 2 to 3 weeks .
I- Treatment of relapses:
1) Corticosteroids:
67. 3) IV immunoglobulins: IVIg 0.4 g/kg
daily for 5 days in acute demyelinating
attacks that do not improve after high dose
of steroid .٭
2) Plasma exchange: indicated in
i) Life-threatening acute demyelination.
ii) Recurrence of symptoms during or
after steroid therapy٭٭ .
73. Oral medication
Fingolimod ( 0,5 mg daily ) act on s1p receptor prevent egress of activated
lymphocyte to circulation from lymph node.
Fumaric acid ( 240 mg twice) it activate transcriptional factor nrf2.
Teriflunamide ( 14 mg ) inhibit pyrimidine synthesis.
Cladribine ( 0.07 mg / kg ) purine nuclside analogue.
Laquinamide ( 0.6 mg ) shift Th1 to Th2 response
74. Monoclonal antibodies
Natalizumab ( 300 mg /28 day ) act on integrin ( VLA4) .
Rituximab ( 375mg /m²/week ) for 2 months , act on CD2O of B cells.
Daclizumab act on CD25 of both T&B cells.
Almetuzumab act on CD52 of both T& B cells.
Ocrelizumab act on CD20 .
Mastinab it bind to tyrosine kinase of mast cells
75. Chemotherapy
Cyclophosphamide
The therapy may be administered orally( 1.5 mg/kg) or intravenously.
The most widely used regimen is monthly pulsed therapy with 800 mg/m2
administered monthly for 1 year, followed by bimonthly treatments in those who
are responders, although numerous other regimens have been proposed,
including the use of combined treatment with methylprednisolone.
Dose adjustments are made based on the peripheral white blood cell (WBC) nadir
acquired on the 14th day following treatment The rationale of this adjustment is
to attenuate the peripheral WBC counts with levels between 1500 and 2000
WBC/mm3.
76. Chemotherapy
METHOTREXATE
Methotrexate inhibits dihydrofolate reductase, an enzyme responsible for the
conversion of dihydrofolate into tetrahydrofolate. Tetrahydrofolate and its
derivatives are essential for purine and thymidylate synthesis and cell
proliferation and growth.
Dose 7.5 mg / week IM.
77. Chemotherapy
AZATHIOPRINE
In some instances,considered as a first-line treatment for those unwilling to use
IFN-b or glatiramer acetate, despite somewhat conflicting data.
The medication targets activation, proliferation, and differentiation of fast-
growing cells, including T and B cells, through inhibition of purine synthesis.
Dose up to 2.5 mg /kg daily.
78. Symptomatic treatment
Spasticity
• Attend to any factors which may exacerbate spasticity, such as noxious
stimuli due to urinary tract infection, infected pressure sores or ulcers,
tight clothing, or an uncomfortable orthotic.
• Educate patients to understand and manage their spasticity.
• Correct posture: avoid positions which favor the pattern of spasticity.
• Physiotherapy
79. Pharmacology:
Oral agents:
–– Tizanidine, an L2 alpha adrenergic antagonist.
–– Baclofen, 5 mg bd, increasing slowly to 10–25 mg three times daily if
tolerated and required
–– Diazepam 5–10 mg three times daily.
–– Dantrolene.
–– Gabapentin.
• Intramuscular injections of botulinum toxin A
• Intrathecal baclofen: • Rarely, nerve blocks are used
Symptomatic treatment
80. Bladder dysfunction
• Detrusor hyper-reflexia:
• Clean intermittent self-catheterization (CISC) is the most effective.
• Anticholinergic agents (reduce urgency but may increase residual volume):
–– Oxybutynin hydrochloride 5 mg tablets,
25–5.0 mg every 6–8 hours.
–– Propantheline bromide 15 mg, four times daily.
–– Amitriptyline 25–100 mg daily.
• Intravesical botulinum toxin is an increasingly promising technique.
Symptomatic treatment
81. Fatigue
• Psychologic counseling.
• Amantadine 100 mg in the morning and afternoon can help in some
cases.
• 4-Aminopyridine (fampridine), and 3-4-diaminopyridine, a potassium
channel blocking agent, may have a role.
Symptomatic treatment
82. Tremors and Ataxia
• Clonazepam 0.5–2.0 mg two or three times daily.
• Ondansetron, a 5-hydroxytryptophan-3 (5-HT3) antagonist, 8 mg IV.
• Carbamazepine.
• Gabapentin.
• Isoniazid and pyridoxine.
• Propranolol.
• Buspirone.
• Surgery. Deep brain stimulation appears promising for tremor, but not
ataxia, in MS.
Symptomatic treatment
83. Cognitive dysfunction and depression
in some cases, cognitive rehabilitation.
There is emerging evidence for acetylcholinesterase inhibitors such as
donepezil.
The treatment of depression is similar to that of a patient who does not
have MS, and includes psychologic counseling and serotonin reuptake
inhibitors such as tricyclic antidepressants. However, particular attention
needs to be paid to adverse effects, as they may exaggerate existing
problems such as sexual dysfunction.
Symptomatic treatment
84. Visual dysfunction
• Monocular blindness or scotoma, diplopia and oscillopsia: this is difficult
to manage, but referral to low vision clinics can be helpful.
• Botulinum toxin injections of oculomotor muscles may reduce persistent
oscillopsia.
• Acquired pendular nystagmus may respond to converging prisms and
isoniazid (and possibly gabapentin).
Symptomatic treatment